Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rhythm Pharmaceuticals (RYTM) Assets Average: 2017-2025

Historic Assets Average for Rhythm Pharmaceuticals (RYTM) over the last 8 years, with Sep 2025 value amounting to $439.8 million.

  • Rhythm Pharmaceuticals' Assets Average rose 18.00% to $439.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $439.8 million, marking a year-over-year increase of 18.00%. This contributed to the annual value of $362.5 million for FY2024, which is 1.37% up from last year.
  • Rhythm Pharmaceuticals' Assets Average amounted to $439.8 million in Q3 2025, which was up 15.83% from $379.7 million recorded in Q2 2025.
  • Rhythm Pharmaceuticals' Assets Average's 5-year high stood at $439.8 million during Q3 2025, with a 5-year trough of $281.2 million in Q2 2022.
  • Moreover, its 3-year median value for Assets Average was $364.1 million (2023), whereas its average is $358.5 million.
  • As far as peak fluctuations go, Rhythm Pharmaceuticals' Assets Average soared by 62.15% in 2021, and later plummeted by 30.61% in 2022.
  • Quarterly analysis of 5 years shows Rhythm Pharmaceuticals' Assets Average stood at $342.7 million in 2021, then increased by 12.66% to $386.0 million in 2022, then declined by 11.03% to $343.5 million in 2023, then rose by 10.03% to $377.9 million in 2024, then rose by 18.00% to $439.8 million in 2025.
  • Its Assets Average stands at $439.8 million for Q3 2025, versus $379.7 million for Q2 2025 and $389.5 million for Q1 2025.